GRI Bio (GRI) shares updated corporate presentation via 8-K filing

Rhea-AI Filing Summary

GRI Bio, Inc. filed a current report to make a new corporate presentation available to the market. The company is furnishing, rather than filing, this information under Regulation FD, which means the materials are provided for informational purposes and are not subject to certain liability provisions of the Exchange Act. The 8-K identifies the presentation as Exhibit 99.1, titled "GRI Bio, Inc. Corporate Presentation" and dated August 20, 2025.

FALSE000182429300018242932025-08-202025-08-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 20, 2025

GRI BIO, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40034

82-4369909

(State or other jurisdiction

(Commission File Number)

(IRS Employer Identification No.)

of incorporation)

2223 Avenida de la Playa, #208

La Jolla, CA 92037

(Address of principal executive offices and zip code)

(619) 400-1170

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001 per share			GRI			The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						GRI Bio, Inc. Corporate Presentation, dated August 20, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 20, 2025

GRI BIO, INC.

By:

/s/ Leanne Kelly

Name:

Leanne Kelly

Title:

Chief Financial Officer

FAQ

What did GRI (GRI Bio, Inc.) disclose in this 8-K?

GRI Bio, Inc. furnished a corporate presentation dated August 20, 2025 as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure).

Is the GRI corporate presentation considered filed with the SEC?

No. The company states the information in Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act.

What exhibit is included with GRI Bio, Inc.’s 8-K?

The 8-K includes one exhibit, Exhibit 99.1, titled "GRI Bio, Inc. Corporate Presentation, dated August 20, 2025."

Which disclosure item does this GRI 8-K use?

The report uses Item 7.01 Regulation FD Disclosure, which is typically used to share informational presentations or updates with the market.

Who signed the GRI Bio, Inc. 8-K?

The report was signed on behalf of GRI Bio, Inc. by Leanne Kelly, Chief Financial Officer, dated August 20, 2025.